Abstract
The year 1952 and the first application of immunoglobulins by Ogden Bruton meant important step not only trearment of humoral immunodeficiencies. Following progress in improvement of immunoglobulin remedies lead to the development of subcutaneous immunoglobulins, which are comparable in efficacy and safety with intravenous immunoglobulins, moreover they allow the self - administration at home.
Thus, subcutanous immunoglobulins significantly incerase patients adherence and compliance at the therapy - crucial and indispensable part of complex care. The latest remedies with facilitated application of subcutaneous immunoglobulins using enzyme hyaluronidase combine propersties of subcutaneous and intravenous immunoglobulins together-subcutaneous administrationof whole month dose to the application site.
This new method brings not only further possibilities how to tailor therapy to our patients with immunodeficiencies, but also open new possibilities of subcutaneous immunoglobulins in different indications such as autoimmune diseases.